These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28885911)

  • 1. Renal denervation: What happened, and why?
    Shishehbor MH; Hammad TA; Thomas G
    Cleve Clin J Med; 2017 Sep; 84(9):681-686. PubMed ID: 28885911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New opportunities of renal denervation].
    Agaeva RA; Danilov NM; Shelkova GV; Matchin YG; Chazova IE
    Ter Arkh; 2020 Jul; 92(6):84-88. PubMed ID: 33346499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
    Epstein M; de Marchena E
    J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous renal sympathetic denervation: 2013 and beyond.
    Froeschl M; Hadziomerovic A; Ruzicka M
    Can J Cardiol; 2014 Jan; 30(1):64-74. PubMed ID: 24365191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
    Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
    Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future.
    Al Raisi SI; Pouliopoulos J; Swinnen J; Thiagalingam A; Kovoor P
    Heart Lung Circ; 2020 Jan; 29(1):94-101. PubMed ID: 31327701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
    Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.
    Persu A; Kjeldsen S; Staessen JA; Azizi M
    Curr Hypertens Rep; 2016 Jan; 18(1):6. PubMed ID: 26739586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal denervation for resistant hypertension: yes.
    Boschetti E; Alrashdi Y; Schillaci G
    Intern Emerg Med; 2016 Jun; 11(4):491-3. PubMed ID: 26970989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal denervation for resistant hypertension and beyond.
    Laffin LJ; Bakris GL
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):133-9. PubMed ID: 25704350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension.
    Schlaich MP
    Am J Hypertens; 2017 Sep; 30(9):847-856. PubMed ID: 28338871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant hypertension in 2017.
    Hans S; Reilly JP
    Curr Opin Cardiol; 2017 Jul; 32(4):389-396. PubMed ID: 28505045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal denervation 2013].
    Spinar J; Vítovec J; Spinarová L
    Vnitr Lek; 2013 Aug; 59(8):724-9. PubMed ID: 24007231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal denervation for uncontrolled hypertension: critical review of the evidence.
    Chen C; Upadhyay A
    Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):114-122. PubMed ID: 27922849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.